Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Observational 2Interventional 2

Sponsor

Cancer Type

Gastrointestinal 16Genitourinary 15Thoracic 10Breast 10Lymphoid 9CNS 6Head & Neck 5Dermatologic 5Other hematologic neoplasm 4Gynecologic 4Plasma cell 3Endocrine 3Tumor-Agnostic 2Other solid neoplasm 2NET 2Myeloid 2Sarcoma 1

Conditions

Neuroendocrine Tumors 2

Interventions

lutetium Lu 177 dotatate 41Everolimus 38Magnetic Resonance Spectroscopy 18Temozolomide 17lanreotide 16gallium Ga 68 dotatate 15Octreotide 14pembrolizumab 13Nivolumab 13Capecitabine 12cabozantinib 11177Lu-octreotide, DOTA(0)-Tyr(3)- 11surufatinib 9pasireotide 9Sunitinib 9Specimen Handling 9Positron Emission Tomography Computed Tomography 93-Iodobenzylguanidine 9Lutetium-177 8Carboplatin 8amino-acid, glucose, and electrolyte solution 6Ipilimumab 6Ga(III)-DOTATOC 6Fluorodeoxyglucose F18 6Etoposide 6Cisplatin 690Y-octreotide, DOTA-Tyr(3)- 6lenvatinib 5copper dotatate CU-64 5Injections 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Positron-Emission Tomography × NET × Clear all
NCT02348749 2025-03-19

18F-MFBG Imaging for Evaluation of Neuroendocrine Malignancies

Memorial Sloan Kettering Cancer Center

Phase 1/2 Completed
48 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT04510311 2025-01-10

Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors

University of Michigan Rogel Cancer Center

Phase EARLY_PHASE1 Completed
32 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡